Radeep Services Pharmaceutical Import Profile — Singapore (DGFT 2022–2026)

Name: Radeep Services Pharmaceutical Import Records from India — 2 Products, $40.3K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Radeep Services — Pharmaceutical Importer Profile (2026) | 2 Products, $40.3K Trade | TransData Nexus

Radeep Services

Pharmaceutical Importer · Singapore · Advanced Oncology Focus · $40.3K Total Trade · DGFT Verified

Radeep Services is a pharmaceutical importer based in Singapore with a total trade value of $40.3K across 2 products in 2 therapeutic categories. Based on 30 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Radeep Services sources from 32 verified Indian suppliers, with Pharma Choice Llp accounting for 32.7% of imports.

Radeep Services — Import Portfolio & Supplier Network

Radeep Services import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Radeep Services?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Pharma Choice Llp	$1.6M	587	32.7%
Univaax	$1.6M	541	31.4%
Hcx Pharmaceuticals Llp	$582.9K	97	11.7%

What Formulations Does Radeep Services Import?

Formulation	Value	Ships
Rabies vaccine,human (2.5iu)	$167.2K	6
Rabies vaccine, human (2.5iu)	$148.6K	12
Rabies vaccine human i.p.	$112.0K	11
Recombinant human erythropoietin alfa 4000iu/ML	$107.2K	4
Rabies vaccine,generic name-rabies vaccine IP,batch	$100.0K	2
Rabio rabies	$78.2K	5
Rabies vaccine,generic name-rabies vaccine IP,batch	$73.1K	2
Rabies vaccine,generic name-rabies vaccine IP, batch	$72.5K	2
Rabies vaccine, human (2.5iu) (zoonovac-v)	$71.3K	2
Zuvirab INJ vials - rabies	$66.7K	6
Recombinant human erythropoietin alfa (4000iu/ML)	$55.7K	7
Renocrit 4000 pfs recombinant human erythropoietin alfa (4000iu/ML)	$55.2K	10
Rabio purified rabies vaccine rabies	$54.2K	2
Rabio injection rabies	$50.0K	1
Rabio purified rabies vaccineanti-rabies	$50.0K	1

Radeep Services imports 1,513 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lenvatinib	Advanced Oncology	$26.7K	18	1.3%	9
2	Adalimumab	Biologics & Immunotherapy	$13.6K	12	1.1%	6

Radeep Services imports 2 pharmaceutical products across 2 categories into Singapore totaling $40.3K.

Radeep Services — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Radeep Services, established on July 6, 1998, is a Singapore-based sole proprietorship specializing in freight transport arrangements and wholesale trade of a diverse range of goods without a dominant product. (companies.sg) The company is headquartered at 77 High Street, #04-06, High Street Plaza, Singapore 179433. While its primary focus is on logistics and wholesale distribution, Radeep Services has a notable presence in the pharmaceutical import sector, particularly in sourcing finished pharmaceutical formulations from India.

Over the period from 2022 to 2026, Radeep Services imported a total of $40,000 USD worth of pharmaceutical products from India, encompassing 30 shipments. The imported products span two therapeutic categories, with a concentration in Advanced Oncology (66.3%) and Biologics & Immunotherapy (33.7%). The top two products imported were Lenvatinib ($27,000 USD) and Adalimumab ($14,000 USD), accounting for 1.3% and 1.1% of the total import value, respectively. This indicates a strategic focus on high-value oncology and immunotherapy treatments.

2Distribution Network

Radeep Services operates from its central office located at 77 High Street, #04-06, High Street Plaza, Singapore 179433. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established distribution network within Singapore. The focus on importing pharmaceutical products from India indicates a streamlined logistics operation capable of handling international shipments efficiently.

3Industry Role

In Singapore's pharmaceutical supply chain, Radeep Services functions primarily as an importer and wholesaler. The company's import activities are centered on sourcing finished pharmaceutical formulations from India, which are then distributed within the Singaporean market. This role positions Radeep Services as a key intermediary between Indian pharmaceutical manufacturers and the local healthcare sector, facilitating the availability of specialized treatments in Singapore.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Radeep Services

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Radeep Services demonstrates a high degree of supplier concentration, with its top five Indian suppliers accounting for 100% of its pharmaceutical imports. The leading suppliers include PHARMA CHOICE LLP and UNIVAAX, each contributing approximately $1.6 million USD in import value. This concentrated sourcing strategy may offer benefits such as volume discounts and streamlined logistics. However, it also introduces risks related to supply chain disruptions, as dependency on a limited number of suppliers can lead to vulnerabilities if any of these suppliers face operational challenges. The stability of these relationships is crucial for maintaining a consistent supply of pharmaceutical products.

2Supply Chain Resilience

The resilience of Radeep Services's supply chain is closely tied to the stability and reliability of its primary Indian suppliers. The company's reliance on a concentrated supplier base means that any disruptions—such as production delays, regulatory issues, or logistical challenges—could significantly impact its ability to meet market demand in Singapore. To mitigate these risks, it would be prudent for Radeep Services to diversify its supplier base and establish contingency plans, including identifying backup suppliers and ensuring compliance with international Good Manufacturing Practice (GMP) standards. Additionally, maintaining a diverse portfolio of pharmaceutical formulations can help buffer against supply chain disruptions.

Importing Pharmaceuticals into Singapore — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Singapore

1Regulatory Authority & Framework

In Singapore, the Health Sciences Authority (HSA) is the primary regulatory body overseeing the importation and supply of pharmaceutical products. The HSA operates under the Health Products Act and the Medicines Act, ensuring that all health products, including medicines, meet standards of safety, quality, and efficacy. (moh.gov.sg) The regulatory framework requires that all medicinal products imported into Singapore be evaluated and approved by the HSA before they can be supplied in the market. (moh.gov.sg)

2Import Licensing & GMP

Importers of pharmaceutical products into Singapore must obtain the necessary licenses from the HSA. For instance, an 'Import License on Consignment Basis' is required for importers who are neither the registrants nor authorized by the registrant to import a registered therapeutic product. (hsa.gov.sg) Additionally, the HSA mandates that manufacturers provide evidence of compliance with Good Manufacturing Practice (GMP) standards. As of October 1, 2024, all new or generic drug applications must be supported by GMP compliance evidence for drug substance manufacturers.

3Quality & Labeling

Radeep Services — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Radeep Services's focus on importing pharmaceutical products in the Advanced Oncology and Biologics & Immunotherapy categories aligns with global healthcare trends emphasizing specialized and high-demand treatments. The market demand for these products in Singapore is driven by an aging population and an increasing prevalence of chronic diseases, necessitating advanced therapeutic options. By concentrating on these therapeutic areas, Radeep Services positions itself to meet critical healthcare needs and capitalize on a growing market segment.

2Sourcing Profile

Radeep Services's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on generic drugs in the oncology and immunotherapy sectors. This approach allows the company to offer cost-effective treatment options while maintaining a high standard of quality. India's robust pharmaceutical manufacturing sector, known for its adherence to international GMP standards, complements Radeep Services's procurement objectives.

3Market Positioning

With its specialized product mix, Radeep Services primarily serves the hospital and healthcare sectors in Singapore, supplying advanced oncology and immunotherapy treatments. The company's role as a wholesaler enables it to distribute these specialized products to hospitals, clinics, and other healthcare providers, ensuring that patients have access to essential therapies.

Seller's Guide — How to Become a Supplier to Radeep Services

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Radeep Services, particularly in the oncology and immunotherapy segments. To capitalize on this opportunity, Indian exporters should focus on meeting the stringent quality standards and regulatory requirements set by the HSA. Additionally, offering competitive pricing and ensuring a reliable supply chain will be crucial in establishing a successful partnership with Radeep Services.

2Requirements & Qualifications

Indian exporters aiming to supply Radeep Services and the Singapore market must ensure that their products are registered with the HSA and comply with GMP standards. Manufacturers must provide evidence of GMP compliance, and products must meet the HSA's quality and labeling requirements. Additionally, importers must obtain the necessary licenses from the HSA, such as the 'Import License on Consignment Basis,' to legally import pharmaceutical products into Singapore.

3How to Approach

Frequently Asked Questions — Radeep Services

What products does Radeep Services import from India?

Radeep Services imports 2 pharmaceutical products across 2 categories. Top imports: Lenvatinib ($26.7K), Adalimumab ($13.6K).

Who supplies pharmaceuticals to Radeep Services from India?

Radeep Services sources from 32 verified Indian suppliers. The primary supplier is Pharma Choice Llp (32.7% of imports, $1.6M).

What is Radeep Services's total pharmaceutical import value?

Radeep Services's total pharmaceutical import value from India is $40.3K, based on 30 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Radeep Services focus on?

Radeep Services imports across 2 categories. The largest: Advanced Oncology (66.3%), Biologics & Immunotherapy (33.7%).

Get Full Radeep Services Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.